Madrigal pharmaceuticals provides an overview of upcoming resmetirom data presentations and reports 2022 third quarter financial results

Conshohocken, pa., nov. 03, 2022 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today provides an overview of upcoming resmetirom phase 3 data presentations and reports third quarter 2022 financial results.
MDGL Ratings Summary
MDGL Quant Ranking